The Myeloma Trial Finder lists clinical trials which are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.

It provides information about clinical trials in the UK. Trials included are not necessarily endorsed by Myeloma UK.

Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332

Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.

There are currently 21 open trials. In 108 locations

What is a Clinical Trial?

Step 2: Choose a Trial

There are currently 21 open trials

Step 3: View Details

Trial Title:

Evaluating patient-based treatment strategies for newly diagnosed myeloma patients (RADAR)

Treatments:

Lenalidomide (Revlimid)
Cyclophosphamide
Bortezomib (Velcade®)
Dexamethasone
Isatuximab
Autologous stem cell transplant

Myeloma stage:

Newly Diagnosed

Trial phase:

II, III

Summary

Summary:

A trial evaluating different treatment strategies for newly diagnosed myeloma patients.

During the trial, patients will be assigned treatments based on how well they respond to initial treatment and the genetic risk status (high or standard) of their myeloma.

Locations

Locations:

University College Hospital, London;
St James' Hospital, Leeds

Who can enter the study?

Who can enter the study?:

Newly diagnosed myeloma patients who are eligible for high-dose therapy and stem cell transplantation (HDT-SCT).

What's involved?

What's involved?:

Patients will receive:

  • Induction treatment: lenalidomide, cyclophosphamide, bortezomib and dexamethasone
  • HDT-SCT

Following HDT-SCT patients will be assigned different treatment groups (A, B, C) depending on their genetic risk status and on how well the myeloma has responded to the initial treatment.

Treatment combinations following HDT-SCT will comprise of either isatuximab, bortezomib, cyclophosphamide, lenalidomide or dexamethasone.

Patients will be required to attend outpatient clinics for regular check-ups and tests.

Clinical Information

Clinical Information
(for Medical Professionals):

A randomised, Phase 2/ 3 trial comparing treatment escalation and de-escalation strategies in transplant eligible, newly diagnosed myeloma patients. For more information, click here.

Find

Find out more about Myeloma UK:

Visit www.myeloma.org.uk

Do you want to talk to someone? Call our myeloma Infoline